Phenotypes Associated with This Genotype

Genotype
MGI:5514395

• Allelic Composition: Gt(ROSA)26Sor^tm1(DTA)Vlcg/Gt(ROSA)26Sor^tm1(DTA)Vlcg; Tg(BGLAP-cre/ERT2)#Stko/0
• Genetic Background: involves: 129S1/Sv * FVB/N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

homeostasis/metabolism

increased energy expenditure ( J:201507 )

• in tamoxifen-treated mice with no improvement after osteocalcin administration

increased carbon dioxide production ( J:201507 )

• in tamoxifen-treated mice

increased oxygen consumption ( J:201507 )

• in tamoxifen-treated mice

abnormal glucose homeostasis ( J:201507 )

decreased insulin secretion ( J:201507 )

• in tamoxifen-treated mice

increased circulating glucose level ( J:201507 )

• 1.8-fold in tamoxifen-treated mice

• however, osteocalcin administration rescues phenotype

hyperglycemia ( J:201507 )

• in tamoxifen-treated mice

impaired glucose tolerance ( J:201507 )

• in tamoxifen-treated mice

• however, osteocalcin administration rescues phenotype

insulin resistance ( J:201507 )

• in tamoxifen-treated mice with partial rescue following osteocalcin administration

abnormal hormone level ( J:201507 )

• increased serum resistin in tamoxifen-treated mice with no improvement after osteocalcin administration

• however, serum leptin levels are normal

decreased circulating testosterone level ( J:201507 )

• in tamoxifen-treated mice

• however, osteocalcin administration rescues phenotype

decreased circulating insulin level ( J:201507 )

• -fold in tamoxifen-treated mice

• however, osteocalcin administration rescues phenotype

decreased circulating osteocalcin level ( J:201507 )

• decreased in tamoxifen-treated mice

decreased adiponectin level ( J:201507 )

• in tamoxifen-treated mice

• however, osteocalcin administration rescues phenotype

abnormal lipid homeostasis ( J:201507 )

• decreased ketogenesis/lipogenesis in tamoxifen-treated mice with no improvement after osteocalcin administration

abnormal lipid level ( J:201507 )

• decreased liver fat content in tamoxifen-treated mice with no improvement after osteocalcin administration

skeleton

decreased bone volume ( J:201507 )

• in tamoxifen-treated mice

decreased osteoblast cell number ( J:201507 )

• in tamoxifen-treated mice

decreased bone mass ( J:201507 )

• in tamoxifen-treated mice

decreased bone ossification ( J:201507 )

• reduced bone formation in tamoxifen-treated mice

increased bone resorption ( J:201507 )

• indicated by increased osteoclast surface in tamoxifen-treated mice

adipose tissue

decreased white fat cell number ( J:201507 )

• in tamoxifen-treated mice

decreased gonadal fat pad weight ( J:201507 )

• in tamoxifen-treated mice with no improvement after osteocalcin administration

behavior/neurological

increased food intake ( J:201507 )

• in tamoxifen-treated mice with no improvement after osteocalcin administration

decreased locomotor activity ( J:201507 )

• in tamoxifen-treated mice with no improvement after osteocalcin administration

growth/size/body

decreased lean body mass ( J:201507 )

• in tamoxifen-treated mice

• however, osteocalcin administration rescues phenotype

cellular

increased apoptosis ( J:201507 )

• in tamoxifen-treated osteoblasts

decreased pancreatic beta cell proliferation ( J:201507 )

• in tamoxifen-treated mice

• however, osteocalcin administration rescues phenotype

endocrine/exocrine glands

decreased pancreatic beta cell proliferation ( J:201507 )

• in tamoxifen-treated mice

• however, osteocalcin administration rescues phenotype

decreased pancreatic beta cell mass ( J:201507 )

• in tamoxifen-treated mice

• however, osteocalcin administration rescues phenotype

decreased insulin secretion ( J:201507 )

• in tamoxifen-treated mice